GlassScriptPhysician profile
Melissa A Wiley
NPI 1609522556
$2,250.44
in general payments reported to CMS, 2019-2025
16 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $501 · 2023: $1,017 · 2024: $510 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $299.08 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $267.12 | 2022-2023 | Quviviq |
| Abbvie INC. | $253.33 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $214.49 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $186.53 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $137.38 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $129.75 | 2023-2024 | Invega Sustenna |
| Gilead Sciences, INC. | $122.92 | 2023-2025 | Epclusa |
| Lundbeck LLC | $119.61 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Exact Sciences Corporation | $115.07 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $102.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.41 | 2022 | |
| Axsome Therapeutics, INC. | $83.53 | 2023 | Auvelity |
| Indivior INC. | $56.76 | 2023-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.26 | 2023-2024 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $20.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.